Ontology highlight
ABSTRACT: Background
Casirivimab and imdevimab administered together (REGEN-COV™) markedly reduces the risk of hospitalization or death in high-risk, symptomatic individuals with COVID-19. Here, we report phase 3 results of early treatment of asymptomatic, SARS-CoV-2-positive adults and adolescents with subcutaneous REGEN-COV.Methods
Individuals ≥12 years of age were eligible if identified within 96 hours of a household contact being diagnosed as SARS-CoV-2-positive; 314 were randomized 1:1 to receive subcutaneous REGEN-COV 1200mg or placebo. The primary endpoint was the proportion of infected participants without evidence of prior immunity (i.e., SARS-CoV-2-RT-qPCR-positive/seronegative) who subsequently developed symptomatic Covid-19 during a 28-day efficacy assessment period.Results
Subcutaneous REGEN-COV 1200mg significantly prevented progression from asymptomatic to symptomatic disease compared with placebo (31.5% relative risk reduction; 29/100 [29.0%] vs. 44/104 [42.3%], respectively; P=0.0380). REGEN-COV also reduced the overall population burden of high viral load weeks (39.7% reduction vs. placebo; 48 vs. 82 total weeks; P=0.0010) and of symptomatic weeks (45.3% reduction vs. placebo; 89.6 vs. 170.3 total weeks; P=0.0273), the latter corresponding to an approximately 5.6-day reduction per symptomatic participant. Six placebo-treated participants had a Covid-19-related hospitalization or ER visit versus none for those receiving REGEN-COV. The proportion of participants receiving placebo who had ≥1 treatment-emergent adverse events was 48.1% compared to 33.5% for those receiving REGEN-COV, including Covid-19-related (39.7% vs. 25.8%, respectively) or non-Covid-19-related (16.0% vs. 11.0%, respectively) events.Conclusions
Subcutaneous REGEN-COV 1200mg prevented progression from asymptomatic to symptomatic infection, reduced the duration of high viral load and symptoms, and was well tolerated.(ClinicalTrials.gov number, NCT04452318.).
SUBMITTER: O'Brien MP
PROVIDER: S-EPMC8219113 | biostudies-literature | 2021 Jun
REPOSITORIES: biostudies-literature
O'Brien Meagan P MP Forleo-Neto Eduardo E Sarkar Neena N Isa Flonza F Hou Peijie P Chan Kuo-Chen KC Musser Bret J BJ Bar Katharine J KJ Barnabas Ruanne V RV Barouch Dan H DH Cohen Myron S MS Hurt Christopher B CB Burwen Dale R DR Marovich Mary A MA Brown Elizabeth R ER Heirman Ingeborg I Davis John D JD Turner Kenneth C KC Ramesh Divya D Mahmood Adnan A Hooper Andrea T AT Hamilton Jennifer D JD Kim Yunji Y Purcell Lisa A LA Baum Alina A Kyratsous Christos A CA Krainson James J Perez-Perez Richard R Mohseni Rizwana R Kowal Bari B DiCioccio A Thomas AT Stahl Neil N Lipsich Leah L Braunstein Ned N Herman Gary G Yancopoulos George D GD Weinreich David M DM
medRxiv : the preprint server for health sciences 20210918
<h4>Importance</h4>Easy-to-administer antiviral treatments may be used to prevent progression from asymptomatic infection to COVID-19 and to reduce viral carriage.<h4>Objective</h4>Evaluate the efficacy and safety of subcutaneous casirivimab and imdevimab antibody combination (REGEN-COV) to prevent progression from early asymptomatic SARS-CoV-2 infection to COVID-19.<h4>Design</h4>Randomized, double-blind, placebo-controlled, phase 3 study that enrolled asymptomatic close contacts living with a ...[more]